Drugs / SPL7013
Trials 9 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00331032 | Dec 2006 → Nov 2007 | herpes simplex type 2 infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT00370357 | Aug 2006 → Feb 2007 | HIV infectious disease | Starpharma Pty Ltd | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00740584 | Aug 2008 → Mar 2009 | HIV infectious disease, genital herpes simplex type 2 infectious disorder | Starpharma Pty Ltd | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT01437722 | Aug 2011 → Dec 2012 | bacterial vaginosis | Starpharma Pty Ltd | Completed | No outcome recorded |
| Phase 2 | NCT01201057 | Aug 2010 → Mar 2011 | bacterial vaginosis | Starpharma Pty Ltd | Completed | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT02237950 | Oct 2014 → Dec 2016 | bacterial vaginosis | Starpharma Pty Ltd | Completed | No outcome recorded |
| Phase 3 | NCT02236156 | Oct 2014 → Jul 2016 | bacterial vaginosis | Starpharma Pty Ltd | Completed | No outcome recorded |
| Phase 3 | NCT01577537 | Apr → Oct 2012 | bacterial vaginosis | Starpharma Pty Ltd | Completed | No outcome recorded |
| Phase 3 | NCT01577238 | Mar → Jul 2012 | bacterial vaginosis | Starpharma Pty Ltd | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00442910 Comparator | Jul 2007 → Dec 2009 | — | Starpharma Pty Ltd | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SPL7013 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01577537 ↗ |
| Known as | VivaGel | “3%w/w SPL7013 vaginal gel (VivaGel)” NCT00740584 ↗3“3% w/w SPL7013 Gel (VivaGel™)” NCT00370357 ↗ “SPL7013 Gel (VivaGel®)” NCT01437722 ↗ “SPL7013 Gel (VivaGel®)” NCT01201057 ↗ |
| Action | Inhibit | “that inhibits HIV, herpes simplex virus-2, and human papillomavirus in vitro and in animal models.” PMID 21505316 ↗ May 2011 |
| Modality | Other / unclassified | “3% SPL7013 Gel (VivaGel), a novel dendrimer topical microbicide” PMID 21505316 ↗ May 2011 |
| Route | Topical | “applied topically once a day for seven consecutive days” NCT00370357 ↗ |